First-Line Immunosuppressive Therapies for Acquired Hemophilia A: A 25-year Cohort Experience and Network Meta-Analysis Short title: First-Line Immunosuppressive Therapies in AHA

First-Line Immunosuppressive Therapies for Acquired Hemophilia A: A 25-year Cohort Experience and Network Meta-Analysis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20240405005

Enrollment

100

Registered

2024-04-05

Start date

1997-01-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acquired hemophilia Acquired hemophilia A

Interventions

Newly diagnosed acquired hemophilia

Treatment

Acquired hemophilia A

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Newly diagnosed acquired hemophilia patients age 18 years old and above

Exclusion criteria

Exclusion criteria: Congenital hemophilia with inhibitor

Design outcomes

Primary

Measure	Time frame
Complete remission rate Time at diagnosis to time of CR (normalization of factor VIII (more than 50%), undetectable inhibitor, and immunosuppression stopped without relapse) Percentage	—

Secondary

Measure	Time frame
Relapse rate Time of CR to time of relapse ( the reappearance of the FVIII inhibitor after a patient achieved CR, and with or without bleeding symptoms) Percentage,Time to CR Time to diagnosis to time to CR Months	—

Countries

Thailand

Contacts

Public ContactTheera Ruchutrakool

Faculty of Medicine Siriraj hospital Mahidol University

truchutrakool@gmail.com024194449

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026